Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 23, 2005. The report details corporate actions regarding directors' interests in the company's Ordinary Shares and a share repurchase transaction executed on February 23, 2005.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The financial data presented is limited to share transaction details:
- Share Repurchase Price: 1,269.0757 pence per share.
- Treasury Shares Held: 73,918,000 shares (post-transaction).
- Shares in Issue: 5,865,616,754 shares (excluding Treasury shares).
Material Changes
The filing reports the following material changes compared to the prior period:
- Share Repurchase: The company purchased 785,000 Ordinary shares on February 23, 2005, under authority granted at the May 17, 2004 Annual General Meeting.
- Employee Trust Transfers:
- On February 21, 2005, 3,095 shares were transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- On February 22, 2005, 113,190 shares were transferred from the GSK Trust to participants in the same plan.
Guidance, Outlook, and Risks
The filing contains no management guidance, future outlook, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 785,000 share repurchase based on the disclosed price of 1,269.0757 pence.
- Confirm the updated total share count (issued plus treasury) to assess dilution or capital structure changes.
- Review the impact of the GSK Trust transfers on the specific holdings of directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe.
- Check subsequent filings for the remaining authority available for share buybacks under the May 2004 mandate.